Formulation of RNA interference-based Drugs for Pulmonary delivery: Challenges and Opportunities

References

• Phimister EG Feero WG Guttmacher AE . Realizing genomic medicine. N. Engl. J. Med.366 (8), 757–759 (2012).
   PubMed Web of Science ®Google Scholar
• Hannon GJ Rossi JJ . Unlocking the potential of the human genome with RNA interference. Nature431 (7006), 371–378 (2004).
   PubMed Web of Science ®Google Scholar
• Mattick JS Makunin IV . Non-coding RNA. Hum. Mol. Genet. 15 Spec No. 1, R17–R29 (2006).
   PubMed Web of Science ®Google Scholar
• Daka A Peer D . RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev.64 (13), 1508–1521 (2012).
   PubMed Web of Science ®Google Scholar
• Lam JK Chow MY Zhang Y Leung SW . SiRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucleic Acids4, e252 (2015).
   PubMedGoogle Scholar
• Rupaimoole R Slack FJ . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov.16 (3), 203–222 (2017).
   PubMed Web of Science ®Google Scholar
• Lim LP Lau NC Garrett-Engele P et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature433 (7027), 769–773 (2005).
   PubMed Web of Science ®Google Scholar
• Birchall J . Pulmonary delivery of nucleic acids. Expert Opin. Drug Deliv.4 (6), 575–578 (2007).
   PubMed Web of Science ®Google Scholar
• Forbes B O'lone R Allen PP et al. Challenges for inhaled drug discovery and development: induced alveolar macrophage responses. Adv. Drug Deliv. Rev.71, 15–33 (2014).
   PubMed Web of Science ®Google Scholar
• Qiu Y Lam JK Leung SW Liang W . Delivery of RNAi therapeutics to the airways-from bench to bedside. Molecules21 (9), (2016).
   Web of Science ®Google Scholar
• Metzger WJ Nyce JW . Respirable antisense oligonucleotide (RASON) therapy for allergic asthma. BioDrugs12 (4), 237–243 (1999).
   PubMed Web of Science ®Google Scholar
• Nyce JW . Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Expert Opin. Investig. Drugs6 (9), 1149–1156 (1997).
   PubMedGoogle Scholar
• Ball HA Sandrasagra A Tang L Van Scott M Wild J Nyce JW . Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am. J. Pharmacogenomics3 (2), 97–106 (2003).
   PubMedGoogle Scholar
• Liao WP Dong JR Peh HY et al. Oligonucleotide therapy for obstructive and restrictive respiratory diseases. Molecules22 (1), pii: E139 (2017).
   Web of Science ®Google Scholar
• Guimond A Viau E Aube P Renzi PM Paquet L Ferrari N . Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm. Pharmacol. Ther.21 (6), 845–854 (2008).
   PubMed Web of Science ®Google Scholar
• Imaoka H Campbell H Babirad I et al. Tpi asm8 reduces eosinophil progenitors in sputum after allergen challenge. Clin. Exp. Allergy41 (12), 1740–1746 (2011).
   PubMed Web of Science ®Google Scholar
• FeRNAndo FS Khachigian LM . Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J. Mol. Med.79 (12), 695–706 (2001).
   PubMed Web of Science ®Google Scholar
• Greulich T Hohlfeld JM Neuser P et al. A GATA3-specific dnazyme attenuates sputum eosinophilia in eosinophilic copd patients: a feasibility randomized clinical trial. Respir. Res.19 (1), 55 (2018).
   PubMedGoogle Scholar
• Fujita Y Takeshita F Kuwano K Ochiya T . RNAi therapeutic platforms for lung diseases. Pharmaceuticals6 (2), 223–250 (2013).
   Google Scholar
• Labiris NR Dolovich MB . Pulmonary drug delivery. Part i: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol.56 (6), 588–599 (2003).
   PubMed Web of Science ®Google Scholar
• Paranjpe M Muller-Goymann CC . Nanoparticle-mediated pulmonary drug delivery: a review. Int. J. Mol. Sci.15 (4), 5852–5873 (2014).
   PubMed Web of Science ®Google Scholar
• Smola M Vandamme T Sokolowski A . Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine3 (1), 1 (2008).
   PubMed Web of Science ®Google Scholar
• Merkel OM Kissel T . Nonviral pulmonary delivery of siRNA. Acc. Chem. Res.45 (7), 961–970 (2012).
   PubMed Web of Science ®Google Scholar
• Whitsett JA . Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair. J. Clin. Invest.109 (5), 565–569 (2002).
   PubMed Web of Science ®Google Scholar
• Blank F Fytianos K Seydoux E et al. Interaction of biomedical nanoparticles with the pulmonary immune system. J. Nanobiotechnol.15 (1), 6 (2017).
   PubMedGoogle Scholar
• Rubin BK . Secretion properties, clearance, and therapy in airway disease. Transl. Respir. Med.2, 6 (2014).
   PubMedGoogle Scholar
• Foged C . Thermostable subunit vaccines for pulmonary delivery: how close are we?Curr. Pharm. Des.22 (17), 2561–2576 (2016).
   PubMed Web of Science ®Google Scholar
• Kingma PS Whitsett JA . In defense of the lung: surfactant protein a and surfactant protein D. Curr. Opin. Pharmacol.6 (3), 277–283 (2006).
   PubMed Web of Science ®Google Scholar
• Ferguson JS Schlesinger LS . Pulmonary surfactant in innate immunity and the pathogenesis of tuberculosis. Tuber. Lung Dis.80 (4–5), 173–184 (2000).
   PubMedGoogle Scholar
• Lopez-Rodriguez E Perez-Gil J . Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy. Biochim. Biophys. Acta1838 (6), 1568–1585 (2014).
   PubMed Web of Science ®Google Scholar
• Monopoli MP Aberg C Salvati A Dawson KA . Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol.7 (12), 779–786 (2012).
   PubMed Web of Science ®Google Scholar
• Hu Q Bai X Hu G Zuo YY . Unveiling the molecular structure of pulmonary surfactant corona on nanoparticles. ACS Nano.11 (7), 6832–6842 (2017).
   PubMed Web of Science ®Google Scholar
• Hivroz C Chemin K Tourret M Bohineust A . Crosstalk between t lymphocytes and dendritic cells. Crit. Rev. Immunol.32 (2), 139–155 (2012).
   PubMed Web of Science ®Google Scholar
• Webb TJ Sumpter TL Thiele AT Swanson KA Wilkes DS . The phenotype and function of lung dendritic cells. Crit. Rev. Immunol.25 (6), 465–491 (2005).
   PubMed Web of Science ®Google Scholar
• Kawai T Akira S . The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol.11 (5), 373–384 (2010).
   PubMed Web of Science ®Google Scholar
• Akira S Uematsu S Takeuchi O . Pathogen recognition and innate immunity. Cell124 (4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Akira S Takeda K . Toll-like receptor signalling. Nat. Rev. Immunol.4 (7), 499–511 (2004).
   PubMed Web of Science ®Google Scholar
• Nayak S Herzog RW . Progress and prospects: immune responses to viral vectors. Gene Ther.17 (3), 295–304 (2010).
   PubMed Web of Science ®Google Scholar
• Thanki K Falkenberg E Gangloff M Foged C . Immune reactions in the delivery of RNA interference-based therapeutics: mechanisms and opportunities. In : Immune Effects of Biopharmaceuticals and Nanomedicine. BawaRSzebeniJWebsterTAudetteG ( Eds). Pan Stanford Publishing Pte. Ltd, Singapore, 1–32 (2017).
   Google Scholar
• Watts JK Deleavey GF Damha MJ . Chemically modified siRNA: tools and applications. Drug Discov. Today13 (19–20), 842–855 (2008).
   PubMed Web of Science ®Google Scholar
• Behlke MA . Chemical modification of siRNAs for in vivo use. Oligonucleotides18 (4), 305–319 (2008).
   PubMed Web of Science ®Google Scholar
• Bramsen JB Kjems J . Development of therapeutic-grade small interfering RNAs by chemical engineering. Front. Genet.3, 154 (2012).
   PubMedGoogle Scholar
• Eberle F Giessler K Deck C et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J. Immunol.180 (5), 3229–3237 (2008).
   PubMed Web of Science ®Google Scholar
• Backer J Marchal T . Taming the cost of respiratory drug development (2010). https://www.ansys.com/-/media/ansys/corporate/resourcelibrary/article/aa-v4-i2-taming-cost-of-respiratory-drug-development.pdf.
   Google Scholar
• Gutbier B Kube SM Reppe K et al. Rnai-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. Pulm. Pharmacol. Ther.23 (4), 334–344 (2010).
   PubMed Web of Science ®Google Scholar
• Geyer A Lorenzer C Gehrig S et al. Fluorescence- and computed tomography for assessing the biodistribution of siRNA after intratracheal application in mice. Int. J. Pharm.525 (2), 359–366 (2017).
   PubMedGoogle Scholar
• Uemura Y Hagiwara K Kobayashi K . The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung. PLoS ONE12 (11), e0187286 (2017).
   PubMed Web of Science ®Google Scholar
• Davis ME . Non-viral gene delivery systems. Curr. Opin. Biotechnol.13 (2), 128–131 (2002).
   PubMed Web of Science ®Google Scholar
• Putnam D . Polymers for gene delivery across length scales. Nat. Mater.5 (6), 439–451 (2006).
   PubMed Web of Science ®Google Scholar
• Boussif O Lezoualch F Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in-vivo – polyethylenimine. Proc. Natl Acad. Sci. USA92 (16), 7297–7301 (1995).
   PubMed Web of Science ®Google Scholar
• Di Gioia S Conese M . Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. Drug Des. Devel. Ther.2, 163–188 (2009).
   PubMedGoogle Scholar
• Richard I Thibault M De Crescenzo G Buschmann MD Lavertu M . Ionization behavior of chitosan and chitosan–DNA polyplexes indicate that chitosan has a similar capability to induce a proton-sponge effect as PEI. Biomacromolecules14 (6), 1732–1740 (2013).
   PubMed Web of Science ®Google Scholar
• Haensler J Szoka FC Jr . Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem.4 (5), 372–379 (1993).
   PubMed Web of Science ®Google Scholar
• Yamagata M Kawano T Shiba K Mori T Katayama Y Niidome T . Structural advantage of dendritic poly(l-lysine) for gene delivery into cells. Bioorganic Med. Chem.15 (1), 526–532 (2007).
   PubMed Web of Science ®Google Scholar
• Tong H Wang C Huang Y et al. Polyethylenimine600-beta-cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells. Int. J. Nanomedicine8, 1935–1946 (2013).
   PubMed Web of Science ®Google Scholar
• Kichler A Leborgne C Danos O Bechinger B . Characterization of the gene transfer process mediated by histidine-rich peptides. J. Mol. Med.85 (2), 191–201 (2007).
   PubMed Web of Science ®Google Scholar
• Nel AE Madler L Velegol D et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater.8 (7), 543–557 (2009).
   PubMed Web of Science ®Google Scholar
• Kim BJ Cho SW Jeon YJ et al. Intranasal delivery of duox2 DNA using cationic polymer can prevent acute influenza a viral infection in vivo lung. Appl. Microbiol. Biotechnol.102 (1), 105–115 (2018).
   PubMed Web of Science ®Google Scholar
• Godbey WT Wu KK Mikos AG . Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J. Biomed. Mater. Res.45 (3), 268–275 (1999).
   PubMed Web of Science ®Google Scholar
• Son S Namgung R Kim J Singha K Kim WJ . Bioreducible polymers for gene silencing and delivery. Acc. Chem. Res.45 (7), 1100–1112 (2012).
   PubMed Web of Science ®Google Scholar
• Petersen H Kunath K Martin AL et al. Star-shaped poly(ethylene glycol)-block-polyethylenimine copolymers enhance DNA condensation of low molecular weight polyethylenimines. Biomacromolecules3 (5), 926–936 (2002).
   PubMed Web of Science ®Google Scholar
• Kichler A Chillon M Leborgne C Danos O Frisch B . Intranasal gene delivery with a polyethylenimine-PEG conjugate. J. Control. Rel.81 (3), 379–388 (2002).
   PubMed Web of Science ®Google Scholar
• Yang J Hendricks W Liu GS et al. A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc. Natl Acad. Sci. USA110 (36), 14717–14722 (2013).
   PubMed Web of Science ®Google Scholar
• Benns JM Maheshwari A Furgeson DY Mahato RI Kim SW . Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J. Drug Target.9 (2), 123–139 (2001).
   PubMed Web of Science ®Google Scholar
• Sagara K Kim SW . A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes. J. Control. Release79 (1–3), 271–281 (2002).
   PubMed Web of Science ®Google Scholar
• Merdan T Callahan J Petersen H et al. Pegylated polyethylenimine-fab’ antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug. Chem.14 (5), 989–996 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas M Klibanov AM . Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc. Natl Acad. Sci. USA99 (23), 14640–14645 (2002).
   PubMed Web of Science ®Google Scholar
• Lee M Rentz J Han SO Bull DA Kim SW . Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther.10 (7), 585–593 (2003).
   PubMed Web of Science ®Google Scholar
• Merkel OM Beyerle A Librizzi D et al. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm.6 (4), 1246–1260 (2009).
   PubMedGoogle Scholar
• Beyerle A Braun A Merkel O Koch F Kissel T Stoeger T . Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J. Control. Rel.151 (1), 51–56 (2011).
   PubMed Web of Science ®Google Scholar
• Grosse S Aron Y Honore I et al. Lactosylated polyethylenimine for gene transfer into airway epithelial cells: role of the sugar moiety in cell delivery and intracellular trafficking of the complexes. J. Gene Med.6 (3), 345–356 (2004).
   PubMed Web of Science ®Google Scholar
• Grosse S Thevenot G Aron Y et al. In vivo gene delivery in the mouse lung with lactosylated polyethylenimine, questioning the relevance of in vitro experiments. J. Control. Rel.132 (2), 105–112 (2008).
   PubMed Web of Science ®Google Scholar
• Qiu YS Chow MYT Liang WL Chung WWY Mak JCW Lam JKW . From pulmonary surfactant, synthetic kl4 peptide as effective siRNA delivery vector for pulmonary delivery. Mol. Pharm.14 (12), 4606–4617 (2017).
   PubMedGoogle Scholar
• Bohr A Tsapis N Andreana I et al. Anti-inflammatory effect of anti-TNF-alpha siRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model. Biomacromolecules18 (8), 2379–2388 (2017).
   PubMed Web of Science ®Google Scholar
• Feldmann DP Cheng Y Kandil R et al. In vitro and in vivo delivery of siRNA via viper polymer system to lung cells. J. Control. Rel.276, 50–58 (2018).
   PubMed Web of Science ®Google Scholar
• Du J Xu Z Liu Q et al. Atg101 single-stranded antisense RNA-loaded triangular DNA nanoparticles control human pulmonary endothelial growth via regulation of cell macroautophagy. ACS Appl. Mater. Interfaces9 (49), 42544–42555 (2017).
   PubMed Web of Science ®Google Scholar
• De Backer L Braeckmans K Stuart MC Demeester J De Smedt SC Raemdonck K . Bio-inspired pulmonary surfactant-modified nanogels: a promising siRNA delivery system. J. Control. Rel.206, 177–186 (2015).
   PubMed Web of Science ®Google Scholar
• Taratula O Kuzmov A Shah M Garbuzenko OB Minko T . Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Rel.171 (3), 349–357 (2013).
   PubMed Web of Science ®Google Scholar
• Schlosser K Taha M Stewart DJ . Systematic assessment of strategies for lung-targeted delivery of microRNA mimics. Theranostics8 (5), 1213–1226 (2018).
   PubMed Web of Science ®Google Scholar
• Yan YF Liu L Xiong H et al. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc. Natl Acad. Sci. Usa113 (39), E5702–E5710 (2016).
   PubMed Web of Science ®Google Scholar
• Yan YF Xiong H Zhang XY Cheng Q Siegwart DJ . Systemic mRNA delivery to the lungs by functional polyester-based carriers. Biomacromolecules18 (12), 4307–4315 (2017).
   PubMed Web of Science ®Google Scholar
• Yan Y Xue L Miller JB et al. One-pot synthesis of functional poly(amino ester sulfide)s and utility in delivering pdna and siRNA. Polymer72, 271–280 (2015).
   PubMed Web of Science ®Google Scholar
• Yan YF Siegwart DJ . Scalable synthesis and derivation of functional polyesters bearing ene and epoxide side chains. Polym. Chem.5 (4), 1362–1371 (2014).
   Web of Science ®Google Scholar
• Yan Y Zhou K Xiong H et al. Aerosol delivery of stabilized polyester–siRNA nanoparticles to silence gene expression in orthotopic lung tumors. Biomaterials118, 84–93 (2017).
   PubMed Web of Science ®Google Scholar
• Eltoukhy AA Siegwart DJ Alabi CA Rajan JS Langer R Anderson DG . Effect of molecular weight of amine end-modified poly(beta-amino ester)s on gene delivery efficiency and toxicity. Biomaterials33 (13), 3594–3603 (2012).
   PubMed Web of Science ®Google Scholar
• Kaczmarek JC Patel AK Kauffman KJ et al. Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew. Chem. Int. Ed. Engl.55 (44), 13808–13812 (2016).
   PubMed Web of Science ®Google Scholar
• Polach KJ Matar M Rice J et al. Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol. Pharm.20 (1), 91–100 (2012).
   Google Scholar
• Mclendon JM Joshi SR Sparks J et al. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J. Control. Rel.210, 67–75 (2015).
   PubMed Web of Science ®Google Scholar
• Li W Szoka FC Jr . Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res.24 (3), 438–449 (2007).
   PubMed Web of Science ®Google Scholar
• Arruda DC Hoffmann C Charrueau C Bigey P Escriou V . Innovative nonviral vectors for small-interfering RNA delivery and therapy. In : Nanostructures for Novel Therapy. FicaiDGrumezescuA ( Eds). Elsevier Inc., Amsterdam, Netherlands, 713–740 (2017).
   Google Scholar
• Dan N Danino D . Structure and kinetics of lipid-nucleic acid complexes. Adv. Colloid Interface Sci.205, 230–239 (2014).
   PubMed Web of Science ®Google Scholar
• Lv HT Zhang SB Wang B Cui SH Yan J . Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Rel.114 (1), 100–109 (2006).
   PubMed Web of Science ®Google Scholar
• Farhood H Serbina N Huang L . The role of dioleoyl phosphatidylethanolamine in cationic liposome-mediated gene-transfer. Biochim. Biophys. Acta Biomembr.1235 (2), 289–295 (1995).
   PubMed Web of Science ®Google Scholar
• Zabner J . Cationic lipids used in gene transfer. Adv. Drug Deliv. Rev.27 (1), 17–28 (1997).
   PubMed Web of Science ®Google Scholar
• Heyes J Palmer L Bremner K Maclachlan I . Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Rel.107 (2), 276–287 (2005).
   PubMed Web of Science ®Google Scholar
• Akinc A Zumbuehl A Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol.26 (5), 561–569 (2008).
   PubMed Web of Science ®Google Scholar
• Love KT Mahon KP Levins CG et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA107 (5), 1864–1869 (2010).
   PubMed Web of Science ®Google Scholar
• Goldberg M . Lipidoids: a combinatorial approach to siRNA delivery. In : RNA interference from Biology to Therapeutics. HowardK ( Ed.). Springer, Boston, MA, USA, 143–160 (2013).
   Google Scholar
• De Groot AM Thanki K Gangloff M et al. Immunogenicity testing of lipidoids in vitro and in silico: modulating lipidoid-mediated tlr4 activation by nanoparticle design. Mol. Ther. Nucleic Acids11, 159–169 (2018).
   PubMedGoogle Scholar
• Thanki K Zeng X Justesen S et al. Engineering of small interfering RNA-loaded lipidoid-poly(dl-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: a quality by design-based approach. Eur. J. Pharm. Biopharm.120, 22–33 (2017).
   PubMed Web of Science ®Google Scholar
• Semple SC Akinc A Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol.28 (2), 172–176 (2010).
   PubMed Web of Science ®Google Scholar
• Karras JG Geary RS Gregory SA . Inhaled antisense oligonucleotide therapies: inspiration and progress. Drug Discov. Today3 (3), 335–341 (2006).
   Google Scholar
• Brain JD Valberg PA . Deposition of aerosol in the respiratory tract. Am. Rev. Respir. Dis.120 (6), 1325–1373 (1979).
   PubMedGoogle Scholar
• Sung JC Pulliam BL Edwards DA . Nanoparticles for drug delivery to the lungs. Trends. Biotechnol.25 (12), 563–570 (2007).
   PubMed Web of Science ®Google Scholar
• Lippmann M Yeates DB Albert RE . Deposition, retention, and clearance of inhaled particles. Br. J. Ind. Med.37 (4), 337–362 (1980).
   PubMedGoogle Scholar
• Pilcer G Amighi K . Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm.392 (1–2), 1–19 (2010).
   PubMed Web of Science ®Google Scholar
• Mainelis G Seshadri S Garbuzenko OB Han T Wang Z Minko T . Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J. Aerosol. Med. Pulm. Drug Deliv.26 (6), 345–354 (2013).
   PubMed Web of Science ®Google Scholar
• Conti DS Brewer D Grashik J Avasarala S Da Rocha SRP . Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol. Pharm.11 (6), 1808–1822 (2014).
   PubMedGoogle Scholar
• Newman SP . Therapeutic inhalation agents and devices–effectiveness in asthma and bronchitis. Postgrad. Med.76 (5), 194–203 (1984).
   PubMed Web of Science ®Google Scholar
• Mangal S Gao W Li TL Zhou Q . Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol. Sin.38 (6), 782–797 (2017).
   PubMed Web of Science ®Google Scholar
• Bielski E Zhong Q Mirza H et al. Tpp-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations. Int. J. Pharm.527 (1–2), 171–183 (2017).
   PubMedGoogle Scholar
• Yang X Xu Y Cai Y Li H . Novel nano-spray-dried powders for efficient pulmonary drug delivery. J. Control. Rel.213, e117–118 (2015).
   Web of Science ®Google Scholar
• Seville PC Li HY Learoyd TP . Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carrier Syst.24 (4), 307–360 (2007).
   PubMed Web of Science ®Google Scholar
• Bosquillon C Lombry C Preat V Vanbever R . Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Rel.70 (3), 329–339 (2001).
   PubMed Web of Science ®Google Scholar
• Vehring R . Pharmaceutical particle engineering via spray drying. Pharm. Res.25 (5), 999–1022 (2008).
   PubMed Web of Science ®Google Scholar
• Chow MYT Qiu YS Lo FFK et al. Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. Int. J. Pharm.530 (1–2), 40–52 (2017).
   PubMedGoogle Scholar
• Patil HP Murugappan S De Vries-Idema J et al. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. Eur. J. Pharm. Biopharm.93, 231–241 (2015).
   PubMed Web of Science ®Google Scholar
• Schulze J Kuhn S Hendrikx S Schulz-Siegmund M Polte T Aigner A . Spray-dried nanoparticle-in-microparticle delivery systems (NIMDs) for gene delivery, comprising polyethylenimine (pei)-based nanoparticles in a poly(vinyl alcohol) matrix. Small14 (12), e1701810 (2018).
   PubMed Web of Science ®Google Scholar
• Liang WL Kwok PCL Chow MYT et al. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur. J. Pharm. Biopharm.86 (1), 64–73 (2014).
   PubMed Web of Science ®Google Scholar
• Jensen DK Jensen LB Koocheki S et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Control. Rel.157 (1), 141–148 (2012).
   PubMed Web of Science ®Google Scholar
• Mohajel N Najafabadi AR Azadmanesh K et al. Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. Int. J. Pharm.423 (2), 577–585 (2012).
   PubMed Web of Science ®Google Scholar
• Kasai T Gotoh K Nishizawa T et al. Development of a new multi-walled carbon nanotube (MWCNT) aerosol generation and exposure system and confirmation of suitability for conducting a single-exposure inhalation study of MWCNT in rats. Nanotoxicology8 (2), 169–178 (2014).
   PubMed Web of Science ®Google Scholar
• Kasai T Umeda Y Ohnishi M et al. Thirteen-week study of toxicity of fiber-like multi-walled carbon nanotubes with whole-body inhalation exposure in rats. Nanotoxicology9 (4), 413–422 (2015).
   PubMed Web of Science ®Google Scholar
• Arold SP Rosa D Saia FA et al. ISPERSE: a novel inhaled dry powder delivery platform for the delivery of large molecule drugs to the lung for local and systemic treatments. Am. Thorac. Soc.San Francisco, CA, USA, May 18–23 (2012).
   Google Scholar
• Yi J Chen BT Schwegler-Berry D et al. Whole-body nanoparticle aerosol inhalation exposures. J. Vis. Exp. (75), e50263 (2013).
   PubMed Web of Science ®Google Scholar
• Nichols CE Shepherd DL Hathaway QA et al. Reactive oxygen species damage drives cardiac and mitochondrial dysfunction following acute nano-titanium dioxide inhalation exposure. Nanotoxicology12 (1), 32–48 (2018).
   PubMed Web of Science ®Google Scholar
• Phillips JE Zhang X Johnston JA . Dry powder and nebulized aerosol inhalation of pharmaceuticals delivered to mice using a nose-only exposure system. J. Vis. Exp. doi:10.3791/55454(122) (2017) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Pujalte I Serventi A Noel A Dieme D Haddad S Bouchard M . Characterization of aerosols of titanium dioxide nanoparticles following three generation methods using an optimized aerosolization system designed for experimental inhalation studies. Toxics5 (3), 14 (2017).
   PubMed Web of Science ®Google Scholar
• Sellers S Horodnik W House A Wylie J Mauser P Donovan B . The in vitro and in vivo investigation of a novel small chamber dry powder inhalation delivery system for preclinical dosing to rats. Inhal. Toxicol.27 (13), 706–716 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang XD Fedan JS Lewis DM Siegel PD . Asthmalike biphasic airway responses in brown norway rats sensitized by dermal exposure to dry trimellitic anhydride powder. J. Allergy Clin. Immunol.113 (2), 320–326 (2004).
   PubMed Web of Science ®Google Scholar
• Pauluhn J Thiel A . A simple approach to validation of directed-flow nose-only inhalation chambers. J. Appl. Toxicol.27 (2), 160–167 (2007).
   PubMed Web of Science ®Google Scholar
• Carvalho SR Watts AB Peters JI et al. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. Eur. J. Pharm. Biopharm.88 (1), 136–147 (2014).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR Najvar LK Vallor AC et al. Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. J. Antimicrob. Chemother.67 (4), 970–976 (2012).
   PubMed Web of Science ®Google Scholar
• Fioni A Selg E Cenacchi V et al. Investigation of lung pharmacokinetic of the novel PDE4 inhibitor chf6001 in preclinical models: evaluation of the precise inhale technology. J. Aerosol. Med. Pulm. Drug Deliv.31 (1), 61–70 (2018).
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L Padilla-Carlin DJ Sung J et al. Pharmacokinetics of ethionamide delivered in spray-dried microparticles to the lungs of guinea pigs. J. Pharm. Sci.106 (1), 331–337 (2017).
   PubMed Web of Science ®Google Scholar
• Zijlstra GS Brandsma CA Harpe MF et al. Dry powder inhalation of hemin to induce heme oxygenase expression in the lung. Eur. J. Pharm. Biopharm.67 (3), 667–675 (2007).
   PubMed Web of Science ®Google Scholar
• Kaur J Muttil P Verma RK et al. A hand-held apparatus for ‘nose-only’ exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur. J. Pharm. Sci.34 (1), 56–65 (2008).
   PubMed Web of Science ®Google Scholar
• Muttil P Kaur J Kumar K Yadav AB Sharma R Misra A . Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci.32 (2), 140–150 (2007).
   PubMed Web of Science ®Google Scholar
• Verma RK Kaur J Kumar K Yadav AB Misra A . Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother.52 (9), 3195–3201 (2008).
   PubMed Web of Science ®Google Scholar
• Durham PG Young EF Braunstein MS Welch JT Hickey AJ . A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals. Int. J. Pharm.514 (2), 384–391 (2016).
   PubMedGoogle Scholar
• Sinha B Mukherjee B . Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model. Drug Dev. Ind. Pharm.38 (2), 171–179 (2012).
   PubMed Web of Science ®Google Scholar
• Codrons V Vanderbist F Ucakar B Preat V Vanbever R . Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs. J. Pharm. Sci.93 (5), 1241–1252 (2004).
   PubMed Web of Science ®Google Scholar
• Duret C Wauthoz N Merlos R et al. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice. Eur. J. Pharm. Biopharm.81 (3), 627–634 (2012).
   PubMed Web of Science ®Google Scholar
• Gaspar MC Gregoire N Sousa JJ et al. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release plga microspheres. Eur. J. Pharm. Sci.93, 184–191 (2016).
   PubMed Web of Science ®Google Scholar
• Sullivan BP El-Gendy N Kuehl C Berkland C . Pulmonary delivery of vancomycin dry powder aerosol to intubated rabbits. Mol. Pharm.12 (8), 2665–2674 (2015).
   PubMed Web of Science ®Google Scholar
• Codrons V Vanderbist F Verbeeck RK et al. Systemic delivery of parathyroid hormone (1–34) using inhalation dry powders in rats. J. Pharm. Sci.92 (5), 938–950 (2003).
   PubMed Web of Science ®Google Scholar
• Grainger CI Alcock R Gard TG et al. Administration of an insulin powder to the lungs of cynomolgus monkeys using a penn century insufflator. Int. J. Pharm.269 (2), 523–527 (2004).
   PubMedGoogle Scholar
• Beinborn NA Du J Wiederhold NP Smyth HD Williams RO 3rd . Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. Eur. J. Pharm. Biopharm.81 (3), 600–608 (2012).
   PubMed Web of Science ®Google Scholar
• Selg E Ewing P Acevedo F Sjoberg CO Ryrfeldt A Gerde P . Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. J. Aerosol. Med. Pulm. Drug Deliv.26 (4), 181–189 (2013).
   PubMed Web of Science ®Google Scholar
• Sellers S Horodnik W House A et al. The in vitro and in vivo investigation of inhaled migraine therapies using a novel aerosol delivery system consisting of an air pressurized capsule device (APCD) in combination with a PMDI spacer for endotracheal dosing into beagle dogs. Drug Dev. Ind. Pharm.41 (12), 1989–1996 (2015).
   PubMed Web of Science ®Google Scholar
• Tonnis WF Bagerman M Weij M et al. A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals. Eur. J. Pharm. Biopharm.88 (3), 1056–1063 (2014).
   PubMed Web of Science ®Google Scholar
• Kuehl PJ Barrett EG Mcdonald JD et al. Formulation development and in vivo evaluation of a new dry powder formulation of albuterol sulphate in beagle dogs. Pharm. Res.27 (5), 894–904 (2010).
   PubMed Web of Science ®Google Scholar
• Okamoto H Aoki M Danjo K . A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration. J. Pharm. Sci.89 (8), 1028–1035 (2000).
   PubMed Web of Science ®Google Scholar
• Hamishehkar H Emami J Najafabadi AR et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded plga microcapsules using dry powder inhaler in diabetic rats. Biopharm. Drug Dispos.31 (2–3), 189–201 (2010).
   PubMed Web of Science ®Google Scholar
• Okuda T Suzuki Y Kobayashi Y et al. Development of biodegradable polycation-based inhalable dry gene powders by spray freeze drying. Pharmaceutics7 (3), 233–254 (2015).
   PubMed Web of Science ®Google Scholar
• Debnath SK Saisivam S Omri A . Plga ethionamide nanoparticles for pulmonary delivery: development and in vivo evaluation of dry powder inhaler. J. Pharm. Biomed. Anal.145, 854–859 (2017).
   PubMed Web of Science ®Google Scholar